On Wednesday, BriaCell Therapeutics (NASDAQ:BCTX) stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro.

BriaCell Therapeutics announced overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor (CPI) in late-stage metastatic breast cancer.

The company reported a median overall survival of 15.6 months from its most recent patients (treated since 2022) vs. 6.7-9.3 months for similar patients reported in the literature.

These patients are being treated with the same Bria-IMT formulation currently being used in BriaCell’s ongoing Phase 3 pivotal study in metastatic breast cancer.

This represents a substantial improvement over BriaCell’s 13.4 months median overall survival previously reported in December 2023.

“The Bria-IMT regimen is the only investigational drug we have seen to show these impressive survival numbers in heavily pre-treated metastatic breast cancer patients who have failed numerous prior treatments, including immune checkpoint inhibitors and antibody-drug conjugates,” stated Giuseppe Del Priore, BriaCell’s Chief Medical Officer.”

The Phase 2 study enrolled 54 heavily pre-treated metastatic breast cancer patients (average number of prior treatments = 6) who were treated with the Bria-IMT regimen and an immune checkpoint inhibitor.

Price Action: BCTX stock is up 213.1% at $1.94 at last check Wednesday.

Read Next:

“ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Stock Market Game with the #1 “news & everything else” trading tool: Benzinga Pro – Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the full article here

Share.

Leave A Reply

Your road to financial

freedom starts here

With our platform as your starting point, you can confidently navigate the path to financial independence and embrace a brighter future.

Registered address:

First Floor, SVG Teachers Credit Union Uptown Building, Kingstown, St. Vincent and the Grenadines

CFDs are complex instruments and have a high risk of loss due to leverage and are not recommended for the general public. Before trading, consider your level of experience, relevant knowledge, and investment objectives and seek financial advice. Vittaverse does not accept clients from OFAC sanctioned jurisdictions. Also, read our legal documents and make sure you fully understand the risks involved before making any trading decision